Laurent Pharmaceuticals to present at the North American Cystic Fibrosis Conference
Laurent Pharmaceuticals to present at the North American Cystic Fibrosis Conference, November 3-5, 2022, Philadelphia, PA
Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19…
Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death
FDA allows Phase 2 study extension focusing on moderate-to-severe COVID-19 patients and grants Type B meeting to discuss eligibility to Emergency Use Authorization (EUA) and Phase 3 clinical developmentLAU-7b is…